BP102 / BoYuan RunSheng Pharma - LARVOL DELTA

Frontline SHR-1701 Plus BP102 and Chemo Shows Potent Activity in Cervical Cancer (OncLive) - P1b/3 | N=572 | NCT05179239 | "Findings presented at the 2023 ASCO Annual Meeting showed that patients who received the combination (n = 31) achieved an overall response rate (ORR) of 77.4% (95% CI, 58.9%-90.4%); this consisted of 4 complete responses and 20 partial responses. Five patients achieved stable disease and 2 patients experienced disease progression....The disease control rate (DCR) was 93.5% (95% CI, 78.6%-99.2%), as was the 6-month progression-free survival (PFS) rate (95% CI, 76.6%-98.3%). Notably, 96.8% of patients achieved shrinkage in target lesions from baseline. All responses are ongoing."

P1 data • Cervical Cancer • Gynecologic Cancers • Oncology • Solid Tumor

Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jul 2022 ➔ May 2024 | Trial primary completion date: May 2022 ➔ Mar 2024

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD276

B7-H3 CAR-T for Recurrent or Refractory Glioblastoma (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jul 2024 ➔ Aug 2025 | Trial primary completion date: Jun 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD276